Spyre Therapeutics, Inc. - Common Stock (NQ:SYRE)
34.02
+0.40
(+1.17%)
Streaming Delayed Price
Updated: 11:08 AM EST, Dec 15, 2025
Add to My Watchlist
Price and Volume
Detailed Quote| Volume | 135,409 |
| Open | 33.93 |
| Bid (Size) | 33.96 (200) |
| Ask (Size) | 34.08 (100) |
| Prev. Close | 33.62 |
| Today's Range | 33.40 - 34.96 |
| 52wk Range | 10.91 - 35.31 |
| Shares Outstanding | 101,192,921 |
| Dividend Yield | N/A |
Top News
More News
Performance
More News
Read More
12 Health Care Stocks Moving In Friday's After-Market Session ↗
October 10, 2025
Spyre (SYRE) Q2 R&D Up 23% Loss Narrows ↗
August 06, 2025
SYRE Stock Earnings: Spyre Therapeutics Beats EPS for Q2 2024 ↗
August 07, 2024
Frequently Asked Questions
Is Spyre Therapeutics, Inc. - Common Stock publicly traded?
Yes, Spyre Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Spyre Therapeutics, Inc. - Common Stock trade on?
Spyre Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Spyre Therapeutics, Inc. - Common Stock?
The ticker symbol for Spyre Therapeutics, Inc. - Common Stock is SYRE on the Nasdaq Stock Market
What is the current price of Spyre Therapeutics, Inc. - Common Stock?
The current price of Spyre Therapeutics, Inc. - Common Stock is 34.02
When was Spyre Therapeutics, Inc. - Common Stock last traded?
The last trade of Spyre Therapeutics, Inc. - Common Stock was at 12/15/25 11:08 AM ET
What is the market capitalization of Spyre Therapeutics, Inc. - Common Stock?
The market capitalization of Spyre Therapeutics, Inc. - Common Stock is 3.44B
How many shares of Spyre Therapeutics, Inc. - Common Stock are outstanding?
Spyre Therapeutics, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.